Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains
Stewart-Jones, G.; Elbashir, S. M.; Wu, K.; Lee, D.; Renzi, I.; Ying, B.; Koch, M.; Sein, C. E.; Choi, A.; Whitener, B.; Garcia-Dominguez, D.; Henry, C.; Woods, A.; Ma, L.; Montes Berrueta, D.; Avena, L. E.; Quinones, J.; Falcone, S.; Hsiao, C. J.; Scheaffer, S. M.; Thackray, L. B.; White, P.; Diamond, M. S.; Edwards, D. K.; Carfi, A.
Show abstract
With the success of mRNA vaccines against coronavirus disease 2019 (COVID-19), strategies can now focus on improving vaccine potency, breadth, and stability. We present the design and preclinical evaluation of domain-based mRNA vaccines encoding the wild-type spike-protein receptor-binding (RBD) and/or N-terminal domains (NTD). An NTD-RBD linked candidate vaccine, mRNA-1283, showed improved antigen expression, antibody responses, and stability at refrigerated temperatures (2-8{degrees}C) compared with the clinically available mRNA-1273, which encodes the full-length spike protein. In mice administered mRNA-1283 as a primary series, booster, or variant-specific booster, similar or greater immune responses and protection from viral challenge were observed against wild-type, beta, delta, or omicron (BA. 1) compared with mRNA-1273 immunized mice, especially at lower vaccine dosages. These results support clinical assessment of mRNA-1283 (NCT05137236). One Sentence SummaryA domain-based mRNA vaccine, mRNA-1283, is immunogenic and protective against SARS-CoV-2 and emerging variants in mice.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 96%
- mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models 94%
- Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2 93%
Similar papers in this journal
Similar papers in this journal
- Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study 96%
- Addressing SARS-CoV-2 Evolution: Neutralization of Emerging Variants of Concern by the AVX/COVID-12 'Patria' Vaccine Based on HexaPro-S Ancestral Wuhan Spike or Its Updated BA.2.75.2 Version 95%
- Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies 95%
Similar papers in this journal
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains 97%
- Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity 96%
- T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire 95%
Similar papers in this journal
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice 97%
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial 95%
- mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.